Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tenofovir disproxil

- PMLiVE

AZ gets US green light for new Bydureon formulation

Its latest injectable suspension proven to reduce blood sugar levels

- PMLiVE

Kite wins FDA approval for blood cancer drug Yescarta

Becomes the first CAR-T therapy approved in the US for B-cell lymphoma

Gilead Sciences promotes Dr Alessandro Riva to EVP, oncology therapeutics

He's been with the firm since January, when he joined from Novartis

Sanofi reception

Sanofi earmarks €170m for new French vaccines facility

Will expand its Val de Reuil production unit

- PMLiVE

CHMP recommends Teva’s generic version of Astellas’ Advagraf

Committee backs the drug for transplant rejection prophylaxis

Roche Basel Switzerland

Roche wins CHMP nod for Alecensa licence extensions

Lung cancer monotherapy set for a broader European label

Sanofi reception

US court lifts ban on sales of Sanofi’s Praluent

The duo can continue to compete against Amgen's rival PCSK9 Repatha

- PMLiVE

J&J seeks US OK to add CV claim to Invokana label

If approved the treatment could better compete with rivals Jardiance and Victoza

- PMLiVE

NICE backs Sanofi’s Kevzara for routine NHS use

Recommends the RA treatment in combination with methotrexate

Sanofi reception

Sanofi, Regeneron claim EU approval for eczema drug Dupixent

Analysts suggest the product could be worth €5bn at peak

- PMLiVE

Sanofi looks to mobile data to power behavioural analysis

Teams up with Evidation Health for a new digital health partnership

- PMLiVE

Sanofi Genzyme brings The World Vs MS to Denmark

Firm's Communiqué Award winning campaign launches in another local market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links